OC-0266: Automated treatment plan generation for advanced stage NSCLC patients
نویسندگان
چکیده
منابع مشابه
Best Practices in Treatment Selection for Patients With Advanced NSCLC.
Worldwide, lung cancer is the most prevalent form of cancer, and its non-small-cell subtype constitutes up to 85% of cases. Overall, lung cancer is the most common cause of cancer-related death in the United States for both sexes, and its 5-year survival rate is 17%. It is a heterogeneous disease characterized by a variety of biomarkers and differing histologies. Non-small-cell lung cancer may ...
متن کاملAdjuvant treatment for patients with surgically resected advanced-stage melanoma.
KG The first step is to determine the risk of relapse and death for individual patients. Presently, the factors that guide our risk prediction are the presence or absence of a positive sentinel lymph node, the thickness of the tumor, the mitotic rate, and the presence or absence of ulceration. The current American Joint Committee on Cancer (AJCC) melanoma staging manual, published in 2009 by Ba...
متن کاملSignificance of Serum HDGF in Advanced Stage of NSCLC
101 Received February 6, 2017; revised and accepted May 18, 2017. Published online June 7, 2017; doi: 10.1620/tjem.242.101. Correspondence: Yihang Zhang, M.D., Ph.D., Department of Orthopaedics, Shandong Academy of Medical Sciences, #18777, Jingshi Road, Jinan 250062, China. e-mail: [email protected] High Serum HDGF Levels Are Predictive of Bone Metastasis and Unfavorable Prognosis in Non-S...
متن کاملAutomated Plan Generation for Robotic Singulation from Mixed Bins
In this paper, we address the problem of singulation in the context of robotic bin-picking applications, which involves grasping and tangle-free extraction of only one part at a time from a bin of randomized parts. In particular, rather than focussing only on interactions between the gripper and the part to be grasped in an isolated fashion, we are interested in problems where success rate is i...
متن کاملSecond-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
The therapeutic approach for the second-line treatment of patients with advanced non-small cell lung cancer (NSCLC) without actionable mutations has been revolutionized by the recent approval of new effective drugs with various mechanisms of action, including nintedanib, ramucirumab, nivolumab, pembrolizumab, atezolizumab, and afatinib. The recent network meta-analysis of Créquit et al. (BMC Me...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiotherapy and Oncology
سال: 2016
ISSN: 0167-8140
DOI: 10.1016/s0167-8140(16)31515-8